Abstract:
:The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosity items and by the excited cluster (excitement, hostility, uncooperativeness, and poor impulse control); anxious / depressive symptoms were assessed by the PANSS anxious / depressive cluster (somatic concern, anxiety, guilt feelings, and depression). Mean change scores from baseline to endpoint were compared in patients receiving risperidone, haloperidol or placebo by analysis of variance with factors for trial and baseline score included in the model. In all patients, change scores on excitement and grandiosity items and excited and anxious / depressive clusters were significantly greater for risperidone than for haloperidol or placebo. Dropouts due to inefficacy were less frequent with risperidone (5 of 59; 8%) than with haloperidol (7 of 38; 18%) or placebo (8 of 10; 80%). In patients with anxious / depressive symptoms at baseline (anxiety / depression cluster score > or = the median), anxiety / depression scores decreased significantly more with risperidone than with haloperidol, and symptom reduction occurred faster with risperidone. These results are consistent with previous reports and suggest that risperidone is more efficacious than haloperidol for affective symptoms in patients with schizophrenia.
journal_name
Int Clin Psychopharmacoljournal_title
International clinical psychopharmacologyauthors
Peuskens J,Van Baelen B,De Smedt C,Lemmens Pdoi
10.1097/00004850-200015060-00005subject
Has Abstractpub_date
2000-11-01 00:00:00pages
343-9issue
6eissn
0268-1315issn
1473-5857journal_volume
15pub_type
杂志文章,meta分析abstract::The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode s...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/YIC.0000000000000140
更新日期:2016-11-01 00:00:00
abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-198804000-00003
更新日期:1988-04-01 00:00:00
abstract::The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was incre...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-199707000-00003
更新日期:1997-07-01 00:00:00
abstract::The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-200206001-00006
更新日期:2002-06-01 00:00:00
abstract::A group of 13 untreated schizophrenic patients was collected over two and a half years. They were prescribed a standard regime of oral haloperidol, and where possible were transferred to haloperidol decanoate depot injections when their clinical condition stabilised. The progress of their symptoms was monitored weekly...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1986-07-01 00:00:00
abstract::Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200205000-00002
更新日期:2002-05-01 00:00:00
abstract::In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199903000-00012
更新日期:1999-03-01 00:00:00
abstract::Panic disorder has recently been recognized as a distinct sub-type of anxiety which may occur with or without phobic avoidance. Controlled prospective trials have demonstrated the efficacy of the tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of this disorder. The use of benzodiazepines an...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-198601000-00002
更新日期:1986-01-01 00:00:00
abstract::The selective serotonin reuptake inhibitors (SSRIs) have well-established antidepressant activity and have also demonstrated efficacy in a number of anxiety disorders, including panic disorder. The SSRIs, escitalopram and sertraline, are well-tolerated and movement disorders are rarely associated with their use. We pr...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200505000-00010
更新日期:2005-05-01 00:00:00
abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/YIC.0000000000000121
更新日期:2016-05-01 00:00:00
abstract::The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:
更新日期:1999-05-01 00:00:00
abstract::In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199710006-00004
更新日期:1997-10-01 00:00:00
abstract::The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,多中心研究
doi:10.1097/00004850-200507000-00002
更新日期:2005-07-01 00:00:00
abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1999-05-01 00:00:00
abstract::Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199906003-00004
更新日期:1999-06-01 00:00:00
abstract::The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-200109000-00004
更新日期:2001-09-01 00:00:00
abstract::Benzodiazepines are commonly used for behavioral and psychiatric symptoms of dementia, despite their numerous adverse effects and the lack of evidence regarding their efficacy in this context. We studied longitudinal benzodiazepines exposure in incident cases of Alzheimer's disease and related syndromes (ADRS) in Fran...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000312
更新日期:2020-09-01 00:00:00
abstract::Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1097/00004850-200015030-00001
更新日期:2000-05-01 00:00:00
abstract::The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was admi...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000118
更新日期:2016-05-01 00:00:00
abstract::Most depressive disorders can be viewed as recurrent conditions that may reduce quality of life and productivity. Results of controlled clinical trials indicate that patients should receive 4-6 months of continuation therapy after remission of the acute phase of the illness. Patients at risk of recurrent episodes, how...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199300840-00004
更新日期:1993-01-01 00:00:00
abstract::Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionall...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-200303000-00005
更新日期:2003-03-01 00:00:00
abstract::Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/YIC.0000000000000009
更新日期:2014-01-01 00:00:00
abstract::One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:1996-03-01 00:00:00
abstract::A priority in the treatment of depression is to obtain rapid improvement at an early stage. Since depressed patients, who are often convinced that nothing can be done for them, may well have difficulty in adhering to the therapeutic management plan, they can be both uncooperative and neglectful of treatment measures. ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199707003-00005
更新日期:1997-07-01 00:00:00
abstract::Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. I...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1097/01.yic.0000122861.35081.16
更新日期:2004-07-01 00:00:00
abstract::Reports of decreased mortality among patients with schizophrenia who use clozapine may be biased if clozapine is prescribed to relatively healthy patients and if intensive monitoring during its use prevents (under-treatment of) somatic disorder. We aimed to assess whether there is a difference in: (1) somatic comorbid...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000292
更新日期:2020-01-01 00:00:00
abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199803000-00006
更新日期:1998-03-01 00:00:00
abstract::Data from the National Comorbidity Survey (NCS) general population study and the World Health Organization (WHO) primary care study have established that comorbidity between panic and depression is one of the strongest psychiatric associations. The two studies agree that patients with panic-depression comorbidity have...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199804004-00003
更新日期:1998-04-01 00:00:00
abstract::Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists sc...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200405000-00008
更新日期:2004-05-01 00:00:00
abstract::In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinic...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:1999-09-01 00:00:00